RESEARCH MONOGRAPH · KDC-MN-387

Estradiol (Research)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

87/100

The reference estrogen with deep pharmacology and a hormone-therapy literature that's finally rehabilitated

17-beta-estradiol is the principal endogenous estrogen and one of the most thoroughly characterized small molecules in pharmacology. Steroid nucleus, A-ring aromatized, 3-hydroxyl and 17-beta-hydroxyl, the two phenolic hydrogens are what give it the ER binding affinity. Acts as agonist at both ER-alpha and ER-beta with roughly similar affinity but different tissue distribution and downstream transcriptional programs.

The clinical literature is where this gets interesting. The Women's Health Initiative results in 2002 stopped hormone therapy in its tracks based on a combined estrogen-plus-progestin arm that showed increased breast cancer and cardiovascular events. The follow-up analyses over the next two decades, including the WHI estrogen-alone arm and the timing-hypothesis reanalyses by Hodis and Manson, have substantially rehabilitated the role of estradiol when started near menopause rather than years after. The current consensus is much more nuanced than 'hormone therapy is dangerous,' which was the dominant interpretation for fifteen years.

What we like for research applications: estradiol is the cleanest tool compound for ER agonist work, and the SERM/SERD class of selective modulators (tamoxifen, raloxifene, fulvestrant, elacestrant) are basically defined by comparison to it. The receptor coactivator and corepressor literature, the genomic versus nongenomic signaling distinction, the membrane ER work (GPER, the G-protein coupled estrogen receptor) are all active areas where estradiol is the reference.

The neurological and bone effects are honestly underappreciated in the textbook framing. Estradiol has measurable cognitive, mood, and neuroprotective effects that the modern literature is taking more seriously. The Brinton lab work on neurosteroidogenesis is a good entry point.

Sourcing is straightforward. Estradiol base, valerate ester, cypionate, hemihydrate, all available pharmaceutical grade with reliable HPLC purity. Stability in solid form is excellent, in solution it's reasonable but light-sensitive (the A-ring aromaticity makes it UV-active). DMSO or ethanol stocks are standard, keep them dark.

The ethinylestradiol derivative (synthetic, used in oral contraceptives) has different pharmacology because it resists first-pass metabolism, but the underlying receptor pharmacology is the same.

Staying power is essentially permanent.

Evidence: 95
Mechanism: 95
Reliability: 92
Safety: 75
Sourcing: 82
Value: 78
Signal: 85
Staying power: 95

Plain-language summary Intrigue 70 / 100

Estradiol (E2) is the principal endogenous estrogen, made from testosterone and androstenedione by the enzyme aromatase in ovary, fat, brain, and bone tissue. It is a high-affinity full agonist at both estrogen receptor subtypes (ER-alpha and ER-beta), driving classic gene-transcription effects plus rapid membrane-level signaling. Approved across many forms (oral, transdermal patch, gel, vaginal, injectable) for menopausal hormone therapy, postmenopausal osteoporosis prevention, hypoestrogenism in conditions like Turner syndrome, and as part of gender-affirming feminizing therapy. Pharmacokinetics depend heavily on route: oral undergoes large first-pass metabolism, while transdermal forms bypass the liver and produce more physiological plasma levels. Reference estrogen receptor agonist for endocrine research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous estrogen / ER-alpha and ER-beta agonist

17-beta-estradiol; the principal endogenous estrogen and the foundational compound of estrogen pharmacology.

Abstract

Estradiol (17-beta-estradiol, E2; CAS 50-28-2; molecular formula C18H24O2; molecular weight 272.39) is the principal endogenous estrogen, biosynthesized from testosterone (and androstenedione) by aromatase in ovary, adipose tissue, brain, and bone. The compound is a high-affinity full agonist at estrogen receptors ER-alpha and ER-beta (Ki approximately 0.1 nM at both), with downstream genomic effects on estrogen-responsive gene transcription and rapid non-genomic effects through membrane-associated signaling. Approved indications include menopausal hormone therapy (multiple oral, transdermal, vaginal, and parenteral formulations), prevention of postmenopausal osteoporosis, hypoestrogenism (Turner syndrome), and as part of gender-affirming feminizing hormone therapy. Pharmacokinetics depend strongly on formulation: oral micronized estradiol undergoes substantial first-pass metabolism; transdermal forms (patches, gels, sprays) bypass first-pass and produce more physiological plasma levels. Schedule N (non-controlled). Used as the canonical estrogen receptor agonist in research.

Mechanism of action

High-affinity ER-alpha and ER-beta full agonist; genomic transactivation of estrogen-responsive genes plus rapid non-genomic membrane signaling.

Reported research dose ranges

Reported research dose ranges vary across the published literature.

References

Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999.
Stuenkel CA, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015.
Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017.

Read the full monograph

Available as a research-use-only PDF download.

KDC-MN-387

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Estradiol (Research)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs